Global Acute Myeloid Leukemia Treatment Market Report and Forecast 2025-2034

Acute Myeloid Leukemia Treatment Market Outlook

The global acute myeloid Leukemia treatment market is expected to grow at a CAGR of 11.4% during the forecast period of 2024-2032, driven by the rapidly growing number of Leukemia cases, especially among children.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Acute Myeloid Leukemia Treatment Market: Insights

Acute myeloid Leukemia (AML) refers to the type of blood cancer that develops in bone marrow and spreads throughout the blood, central nervous system, spleen, and other parts of the body, affecting the abnormal production of white blood cells. It is diagnosed by the rapid growth of immature leucocytes known as leukemic blasts. Acute and chronic disease are divided based on the rate of disease development and cell type. AML spreads more quickly than chronic conditions do, necessitating urgent medical care.

The DNA mutation in the stem cells in bone marrow produces platelets, red and white blood cells, but due to the mutation, there is an increase in the production of white blood cells, more than required. 

The white blood cells are not fully mature and thus cannot protect and fight properties against harmful microbes. Red blood cells and platelets eventually decrease as the number of white blood cells rises.

The signs and symptoms of AML include fever, pain in bones, weight loss, headaches, shortness of breath, irregular heartbeat, nose/gum bleeding, recurrent infection, difficulty in breathing, and fatigue, among others. Age-related AML development is accompanied by an increase in the incidence of dangerous cytogenetic and molecular abnormalities.

Various tests are required to determine the AML sub-type and acute myeloid Leukemia (AML) status. Some of these tests might have to be repeated after therapy to evaluate the efficacy of the treatment. AML and its sub-types are diagnosed through blood and bone marrow testing; changes in blood cell count, and appearance also aid the diagnosis. There are many pre-treatments testing available in the market, including cardiac tests, blood chemical profiles, and Human Leukocyte Antigen (HLA) type.

There is no permanent cure for ALM as the chances of reoccurrence are relatively high. ALM can be treated by chemotherapy, drug therapy, and radiation therapy.

Epidemiology of Acute Myeloid Leukemia Treatment Market

Acute myeloid Leukemia is most prevalent in High to medium Sociodemographic Index (SDI) regions. The highest incidents of AML per 100,000 population were seen in East Asia, followed by Australia, and Western Europe whereas, the lowest was seen in west sub – Saharan Africa and Central Sub-Saharan Africa.

AML incidence has recently increased in the Asian region, which has led to an increase in clinical trials for new leukemia treatments. According to research by Astellas Pharma Inc., 4,500 patients are diagnosed with AML in Japan each year. In addition, the survey revealed that the prevalence of AML was higher among the elderly population. This illness may place a financial strain on the entire population due to the percentage increase in the geriatric population. 

The prevalence of AML over a five-year period was high in low-income Asia Pacific nations and low in high-income Asia Pacific countries, respectively. The Asia Pacific region is made up of nations that are not only economically developing but also seeing significant annual population growth.

As a result, there is a substantial risk of AML occurrence as these countries populations grow. AML is the most common form of Leukemia , accounting for 1% of all cancers. Of Leukemia , the high SDI region had the most death cases. In the medium SDI and low-middle SDI regions, the age-specific mortality rate (ASDR) sharply increased at the same time. 

Acute Myeloid Leukemia Treatment Market Segmentations:

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Diagnosis Methods

• Biopsy and Bone Marrow Aspiration

• Complete Blood Count and Differential

• Philadelphia Chromosome Presence

• Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis

• Immunophenotyping or Phenotyping by Flow Cytometry

• Polymerase Chain Reaction (PCR)

• Others

Market Breakup by Therapy Type

• Targeted Drugs

• Chemotherapy

• Stem/Bone Marrow Treatment

• Radiation Therapy

• Others

Market Breakup by Treatment Channel

• Public

• Private

Acute Myeloid Leukemia Treatment Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Acute Myeloid Leukemia Treatment Market: Therapeutic Landscape

The goal of acute myeloid Leukemia treatment market is to put leukemia into complete remission. Approximately two out of every three AML patients who receive routine induction chemotherapy (chemo), experience remission. This typically indicates that there are no indications or symptoms of the disease, the blood cell counts return to normal ranges, and the bone marrow has less than 5% blast cells. 

The actual probability of remission is significantly influenced by an individual's unique prognostic factors, including age and the existence of certain genes or chromosome abnormalities in the Leukemia cells. If remission occurs, the patient is typically given further chemo treatment to kill new Leukemia cells, up to 50% of these patients are likely to go into long-term remission, which is affected by prognostics factors, like age, genes, or chromosomal changes. Stem cell transplant as therapy is of high success and higher risk for the patient.

The patient is considered for the treatment based on age, performance status, exposure to chemotherapy, radiotherapy, ADH organ function. While the morphology, immunophenotype, cytogenetics, and molecular NGS are used to characterise AML.

Chemotherapy remains the main type of treatment for AML and researchers are working on the efficacy and reduced side effects of the therapy. Some new chemo drugs include Sapacitabine, Laromustine, and Guadecitabine.

Stem cell transplant treatment differ based on where the blood-forming stem cells come from. Allogeneic stem cell transplant is the most common form of stem cell transplant, the stem cells come from the donor, closely related to the patient whose tissue type known as HLA type.

In autologous transplants, patients’ own stem cells are removed and stored frozen, while the patient receives the chemotherapy/radiation, and stem cells are put back after the therapy.

Targeted drug therapy is the gene-targeted drug specifically attacking the gene changes in the AML cells. 

Some of the Recently Targeted Drugs in the Acute Myeloid Leukemia Treatment Market

FLT3 Inhibitors: Leukemia with a gene mutation in the FLT3 gene can be treated with the FDA-approved FLT3 inhibitors Midostaurin, and Gilteritinib, whereas crenolanib is under trials. 

IDH Inhibitors: A gene with a mutation in IDH1, IDH2 gene, which blocks cells from maturing. IDH inhibitor drugs include Enasidenib, Ivosidenib.

Histone Deacetylase (HDAC) Inhibitors: HDAC are a relatively new class of anti-cancer drugs that have significant effects on epigenetic or non-epigenetic control, killing cancer cells and causing apoptosis and cell cycle arrest. 

BCL-2 Inhibitors: A specific inhibitor of the B-cell lymphoma 2 (Bcl-2) anti-apoptotic protein that may also have pro-apoptotic and anti-cancer properties which include Venetoclax. 

Polo-like kinase (Plk) Inhibitors: A family of serine/threonine kinases, also known as polo-like kinases (PLKs), is important at several stages of mitosis. The PLK1 gene has been the focus of most research. It is an exciting target in oncology because it is overexpressed in a variety of cancer types. The majority of PLK1 inhibitors compete with ATP, which includes Alisertib.

Immunotherapy: To fight the cancerous cells, the immune system is boosted in this therapy, which includes Monoclonal antibodies.

Competitive Landscape of the Acute Myeloid Leukemia Treatment Market

The report gives an in-depth analysis of the key players involved in the market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

• Daiichi Sankyo Company, Limited

• Teva Pharmaceutical Industries Ltd.

• Sanofi S.A.

• Pfizer Inc.

• Oncolyze Inc.

• Syndax Pharmaceuticals Inc.

• AbbVie Inc.

• Amgen Inc.

• Servier Pharmaceutical LLC

• F. Hoffmann-La Roche Ltd

• Viracta Therapeutics, Inc.

• Novartis AG

• Otsuka Holdings Co. Ltd

Key Highlights of the Report